Bristol Myers SquibbRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Item | Q2 2026 print |
|---|---|
| WW Eliquis 2026 outlook | Raised versus the April guide; still expected to increase versus 2025 |
| Company 2026 non-GAAP revenue guide | Raised to about $49.0 billion to $50.0 billion from $46.0 billion to $47.5 billion |
| Company 2026 non-GAAP EPS guide | Raised to $6.75 to $7.00 |
| Period | Growth Portfolio ($B) | Reported YoY | Ex-FX YoY |
|---|---|---|---|
| Q2 2026 | 7.6 | 15% | 14% |
| Asset | Printed status | Setting |
|---|---|---|
| Iberdomide (CELMoD) | PDUFA date August 17, 2026 | Relapsed or refractory multiple myeloma |
| Mezigdomide (CELMoD) | NDA accepted; PDUFA date May 13, 2027 | RRMM with carfilzomib and dexamethasone (SUCCESSOR-2) |
| Reblozyl + JAK inhibitor | sBLA accepted; PDUFA date March 11, 2027 | Myelofibrosis-associated anemia (INDEPENDENCE) |
| Camzyos adolescent sNDA | FDA accepted for priority review (June 1, 2026) | Symptomatic obstructive HCM, ages 12 to under 18 (SCOUT-HCM) |
| Admilparant | Pivotal readout expected by year-end 2026 | Pulmonary fibrosis |
| Milvexian | Pivotal readout expected by year-end 2026 | Secondary stroke prevention, with J&J |